New pill could boost weight loss, study launches
NCT ID NCT06732245
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tests an experimental oral drug, NA-931, alone or with an approved injectable weight-loss medication (tirzepatide), in 224 overweight or obese adults aged 18-80. The main goal is to see how much weight participants lose over 48 weeks compared to placebo. The study also measures changes in waist size and body fat.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 224 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * A written informed consent must be obtained before any study-related assessments are performed. * Men and women between 18 and 80 years, inclusive; women of child-bearing potential (defined as those who are not post-menopausal or post-surgical sterilization) must meet both of the following criteria: * Two negative pregnancy tests (at screening and at randomization, prior to dosing) * Use of intrauterine device, from at least 3 months before the baseline visit through at least 4 months after the last dose of NA-931/placebo oral, and an additional contraceptive (barrier) method from screening through at least 4 months after the last dose of NA-931/placebo oral. * Body mass index (BMI) ≥ 30 or BMI ≥ 27 with one or more obesity-associated comorbidities (e.g., hypertension, insulin resistance, sleep apnea, or dyslipidemia) * Stable body weight (± 5 kg) within 90 days of screening, and body weight \<150 kg * Have a history of at least one self-reported unsuccessful behavioral effort to lose body weight * Able to communicate well with the Investigator, comply with the study requirements and adhere to the diet and activity programs for the study duration Exclusion Criteria: * • History of, or known hypersensitivity to, monoclonal antibody drugs or a contraindication to Tirzepatide (Zepbound® or Mounjaro®) * Use of other investigational drugs at the time of enrollment or within 30 days or 5 half-lives of enrollment, whichever is longer, or longer if required by local regulations * Treatment with any medication for the indication of obesity within the past 30 days before screening * Diagnosis of diabetes requiring current use of any antidiabetic drug or HbA1c ≥ 6.5% Note: Metabolic syndrome is not an exclusion, even if managed with an anti-diabetic drug such as metformin or an SGLT2 inhibitor. A diagnosis of prediabetes or impaired glucose tolerance managed exclusively with non-pharmacologic approaches (e.g., diet and exercise) is not an exclusion. * Any chronic infections likely to interfere with study conduct or interpretation such as hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV). History of hepatitis A or hepatitis C successfully treated is not exclusionary. Active COVID-19 infection. * Donation or loss of 400 mL or more of blood within 8 weeks prior to initial dosing, or longer if required by local regulation, or plasma donation (\> 250 mL) within 14 days prior to the first dose * Any disorder, unwillingness, or inability not covered by any of the other exclusion criteria, which in the Investigator's opinion, might jeopardize the participant's safety or compliance with the protocol
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Obesity and overweight are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
17 sites in 3 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
, Australia, 4101 Biomed Research Unit-NSW-4101-111
South Brisbane, Queensland, 4101, Australia
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
, Victoria, Australia, 3084 Biomed Research Unit-VIC-3084-113
Heidelberg West, Victoria, 3084, Australia
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Biomed Research Unit # 10021-107
New York, New York, 10021, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Biomed Research Unit # 32256-105
Jacksonville, Florida, 32256, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Biomed Research Unit # 33012-104
Hialeah, Florida, 33012, United States
Contact Email: •••••@•••••
-
Biomed Research Unit # 33461-106
Lake Worth, Florida, 33461, United States
Contact Email: •••••@•••••
-
Biomed Research Unit # 77479-108
Sugar Land, Texas, 77479, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Biomed Research Unit # 92121-103
San Diego, California, 92121, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Biomed Research Unit # 94104-101
San Francisco, California, 94104, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Biomed Research Unit #90067-102
Los Angeles, California, 90067, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Biomed Research Unit-NSW-2065-110
Saint Leonards,, New South Wales, 2065, Australia
Contact Email: •••••@•••••
-
Biomed Research Unit-NSW-2100-109
Brookvale, New South Wales, 2100, Australia
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Biomed Research Unit-NZ- 6242-117
Newtown, Wellington Region, 6242, New Zealand
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Biomed Research Unit-NZ-1010-114
Auckland, 1010, New Zealand
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Biomed Research Unit-NZ-2025-115
Papatoetoe, Auckland, 2025, New Zealand
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Biomed Research Unit-VIC-3124-112
Camberwell, Victoria, 3124, Australia
Contact Email: •••••@•••••
-
Hamilton, New Zealand, 3200 Biomed Research Unit-NZ-3200-116
Hamilton, 3200, New Zealand
Contact Email: •••••@•••••
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New injection IBI3046 tested for weight management
- One-Size-Fits-All diets may be outdated: personalized plans put to the test
- Can timing your carbs tame metabolic risk?
- Home visits may boost heart health for pregnant women in nigeria
- Could a diabetes drug protect obese Teens' hearts?
- Could a biweekly shot rival weekly Weight-Loss drugs?